58th American Society of Hematology (ASH) Annual Meeting and Exposition Conference Review

In this review:

Daratumumab in relapsed refractory myeloma; CASTOR analysis
More is not better with respect to consolidation
Daratumumab in relapsed refractory myeloma; Pollux update
Overall survival from the FIRST trial
Venetoclax in relapsed/refractory MM
Minimal residual disease in transplant ineligible myeloma patients
Selinexor, bortezomib, dexamethasone in refractory MM:
Stomp Trial
Selinexor, carfilzomib, dexamethasone in relapsed/ refractory MM
Selinexor and dexamethasone in refractory MM
Pembrolizumab for relapsed/ refractory MM

Please login below to download this issue (PDF)